Eur Thyroid J. 2023 Dec 20;12(6). doi: 10.1530/ETJ-23-0135. Print 2023 Dec 1.
The aim was to evaluate the clinical, ultrasound (US) and, when indicated, the cytological and histological characteristics of autonomously functioning thyroid nodules (AFTN) in consecutive patients.
A prospective, single-centre study was conducted between March 2018 and September 2021. In total, 901 consecutive patients were referred for thyroid workup and of 67 AFTN were evaluated. All enrolled patients underwent 99mTcO4 - scintigraphy, additional 123I scintigraphy only in case of normal serum TSH, evaluation of thyroid function, US examination using European Thyroid Imaging and Reporting Data System (EU-TIRADS), and US-guided fine needle aspiration (FNA) cytology when indicated. All indeterminate FNA samples were subjected to DNA sequencing analysis.
More than half of the evaluated patients with AFTN were euthyroid; median serum TSH was 0.41 (IQR: 0.03-0.97) mU/L. The median AFTN size measured by US was 27.0 (IQR: 21.1-35.0) mm. 28.4% of AFTN were classified as EU-TIRADS score 3 and 71.6% as EU-TIRADS score 4, indicating that the majority of AFTN had intermediate risk for malignancy according to US. Out of the 47 AFTN subjected to cytological evaluation, 24 (51%) yielded indeterminate FNA results. DNA sequencing revealed pathogenic TSHR and GNAS mutations in 60% of cases. No malignancy was detected at final histology in surgically excised AFTN (n = 12).
Of the 67 AFTN evaluated in this study, 50% presented with normal serum TSH, 70% displayed ultrasound features suggesting an intermediate malignancy risk and 50% of the AFTN submitted to cytology yielded indeterminate results. No malignant AFTN was detected.
评估连续患者中自主功能性甲状腺结节(AFTN)的临床、超声(US)以及在有指征的情况下细胞学和组织学特征。
本前瞻性单中心研究于 2018 年 3 月至 2021 年 9 月进行。共对 901 例连续患者进行甲状腺检查,其中评估了 67 例 AFTN。所有入组患者均接受 99mTcO4 闪烁显像,仅在血清 TSH 正常时加做 123I 闪烁显像,评估甲状腺功能,使用欧洲甲状腺成像和报告数据系统(EU-TIRADS)进行 US 检查,并在有指征时进行 US 引导下细针抽吸细胞学检查。所有不确定的 FNA 样本均进行 DNA 测序分析。
评估的 AFTN 患者中超过一半为甲状腺功能正常;中位血清 TSH 为 0.41(IQR:0.03-0.97)mU/L。US 测量的 AFTN 中位大小为 27.0(IQR:21.1-35.0)mm。28.4%的 AFTN 分类为 EU-TIRADS 评分 3 级,71.6%为 EU-TIRADS 评分 4 级,这表明根据 US,大多数 AFTN 的恶性肿瘤风险为中度。47 例 AFTN 行细胞学评估,24 例(51%)结果为不确定的 FNA。DNA 测序显示 60%的病例存在致病性 TSHR 和 GNAS 突变。在手术切除的 AFTN(n=12)中最终组织学未发现恶性肿瘤。
在本研究中评估的 67 例 AFTN 中,50%的患者血清 TSH 正常,70%的患者 US 表现提示中度恶性风险,50%的 AFTN 行细胞学检查结果为不确定。未发现恶性 AFTN。